Cargando…

Hyperprolactinaemia with amisulpride

Amisulpride, a substituted benzamide derivative, is a second-generation antipsychotic that preferentially binds to D2/D3 receptors in limbic rather than striatal structures. High dosage preferentially antagonizes postsynaptic receptors, resulting in reduced dopamine transmission; and low dosage bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj, Rajnish, Sidhu, Balwant Singh
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745860/
https://www.ncbi.nlm.nih.gov/pubmed/19771309
http://dx.doi.org/10.4103/0019-5545.39761
_version_ 1782172007774814208
author Raj, Rajnish
Sidhu, Balwant Singh
author_facet Raj, Rajnish
Sidhu, Balwant Singh
author_sort Raj, Rajnish
collection PubMed
description Amisulpride, a substituted benzamide derivative, is a second-generation antipsychotic that preferentially binds to D2/D3 receptors in limbic rather than striatal structures. High dosage preferentially antagonizes postsynaptic receptors, resulting in reduced dopamine transmission; and low dosage blocks presynaptic receptors, resulting in enhanced transmission. Hyperprolactinaemia may occur in patients receiving amisulpride at low dose of 50 mg/day and results in galactorrhoea, amenorrhea and sexual dysfunction. The symptom ameliorates on withdrawing the drug, switching to non-prolactin-elevating drugs, and timely management with dopamine agonist.
format Text
id pubmed-2745860
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-27458602009-09-21 Hyperprolactinaemia with amisulpride Raj, Rajnish Sidhu, Balwant Singh Indian J Psychiatry Case Report Amisulpride, a substituted benzamide derivative, is a second-generation antipsychotic that preferentially binds to D2/D3 receptors in limbic rather than striatal structures. High dosage preferentially antagonizes postsynaptic receptors, resulting in reduced dopamine transmission; and low dosage blocks presynaptic receptors, resulting in enhanced transmission. Hyperprolactinaemia may occur in patients receiving amisulpride at low dose of 50 mg/day and results in galactorrhoea, amenorrhea and sexual dysfunction. The symptom ameliorates on withdrawing the drug, switching to non-prolactin-elevating drugs, and timely management with dopamine agonist. Medknow Publications 2008 /pmc/articles/PMC2745860/ /pubmed/19771309 http://dx.doi.org/10.4103/0019-5545.39761 Text en © Indian Journal of Psychiatry http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Raj, Rajnish
Sidhu, Balwant Singh
Hyperprolactinaemia with amisulpride
title Hyperprolactinaemia with amisulpride
title_full Hyperprolactinaemia with amisulpride
title_fullStr Hyperprolactinaemia with amisulpride
title_full_unstemmed Hyperprolactinaemia with amisulpride
title_short Hyperprolactinaemia with amisulpride
title_sort hyperprolactinaemia with amisulpride
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745860/
https://www.ncbi.nlm.nih.gov/pubmed/19771309
http://dx.doi.org/10.4103/0019-5545.39761
work_keys_str_mv AT rajrajnish hyperprolactinaemiawithamisulpride
AT sidhubalwantsingh hyperprolactinaemiawithamisulpride